ArticleThe Journal of infectious diseases2016
Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
Article in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Efficacy and safety of COVID-19 vaccines.The Cochrane database of systematic reviews · 2022Pooled it
- Evaluation of the Prevention and Control Efficacy of Different Immunization Regimens Against Porcine Epidemic Diarrhea Virus.Transboundary and emerging diseases · 2026Article
- Article
- Evolution and immunopathology of chikungunya virus informs therapeutic development.Disease models & mechanisms · 2023Review
- Virus-like particle vaccines with epitopes from porcine epidemic virus and transmissible gastroenteritis virus incorporated into self-assembling ADDomer platform provide clinical immune responses in piglets.Frontiers in immunology · 2023Article
- Comparing the Immunogenicity and Protective Effects of Three MERS-CoV Inactivation Methods in Mice.Vaccines · 2022Article
- Expression and immunogenicity of nsp10 protein of porcine epidemic diarrhea virus.Research in veterinary science · 2022Article
- An mRNA vaccine encoding Chikungunya virus E2-E1 protein elicits robust neutralizing antibody responses and CTL immune responses.Virologica Sinica · 2022Article
- Article
- Novel insights into the treatment of SARS-CoV-2 infection: An overview of current clinical trials.International journal of biological macromolecules · 2020Review
- Porcine epidemic diarrhea virus: Molecular mechanisms of attenuation and vaccines.Microbial pathogenesis · 2020Review
- Middle East Respiratory Syndrome Coronavirus (MERS-CoV): State of the Science.Microorganisms · 2020Review
- Arthritogenic Alphaviruses: A Worldwide Emerging Threat?Microorganisms · 2019Review
- Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.PLoS neglected tropical diseases · 2019Article
- Recent Progress in Vaccine Development Against Chikungunya Virus.Frontiers in microbiology · 2019Review
- Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus.Frontiers in microbiology · 2019Review
- Cellular and Molecular Immune Response to Chikungunya Virus Infection.Frontiers in cellular and infection microbiology · 2018Review
- Vaccines for epidemic infections and the role of CEPI.Human vaccines & immunotherapeutics · 2017Review
- Detection, isolation, and characterization of chikungunya viruses associated with the Pakistan outbreak of 2016-2017.Virologica Sinica · 2017Article
- Recent progress on chikungunya virus research.Virologica Sinica · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chikungunya virus (CHIKV) is a global public health threat, having been identified in >60 countries in Asia, Africa, Europe, and the Americas. There is no cure for or licensed vaccine against CHIKV infection. Initial attempts at CHIKV vaccine development began in the early 1960s. Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current approaches being evaluated. Success of these approaches is dependent on a safe, well-tolerated vaccine that is immunogenic and deployable in regard to manufacturing, stability, and delivery characteristics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.